Hexagon Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,032
| Closed | -$15.9K | – | 1557 |
|
|
2025
Q1 | $15.9K | Sell |
1,032
-106
| -9% | -$1.63K | ﹤0.01% | 824 |
|
|
2024
Q4 | $25.1K | Buy |
1,138
+310
| +37% | +$6.83K | ﹤0.01% | 707 |
|
|
2024
Q3 | $14.9K | Buy |
828
+70
| +9% | +$1.26K | ﹤0.01% | 805 |
|
|
2024
Q2 | $12.3K | Sell |
758
-10
| -1% | -$163 | ﹤0.01% | 810 |
|
|
2024
Q1 | $10.8K | Buy |
768
+10
| +1% | +$141 | ﹤0.01% | 839 |
|
|
2023
Q4 | $7.91K | Buy |
758
+528
| +230% | +$5.51K | ﹤0.01% | 875 |
|
|
2023
Q3 | $2.35K | Sell |
230
-2
| -0.9% | -$20 | ﹤0.01% | 1042 |
|
|
2023
Q2 | $1.75K | Buy |
232
+34
| +17% | +$256 | ﹤0.01% | 1103 |
|
|
2023
Q1 | $1.75K | Sell |
198
-126
| -39% | -$1.12K | ﹤0.01% | 1091 |
|
|
2022
Q4 | $2.96K | Buy |
324
+14
| +5% | +$128 | ﹤0.01% | 1009 |
|
|
2022
Q3 | $3K | Buy |
310
+116
| +60% | +$1.12K | ﹤0.01% | 1052 |
|
|
2022
Q2 | $1K | Buy |
194
+108
| +126% | +$557 | ﹤0.01% | 1130 |
|
|
2022
Q1 | $1K | Hold |
86
| – | – | ﹤0.01% | 889 |
|
|
2021
Q4 | $1K | Hold |
86
| – | – | ﹤0.01% | 824 |
|
|
2021
Q3 | $1K | Hold |
86
| – | – | ﹤0.01% | 824 |
|
|
2021
Q2 | $1K | Hold |
86
| – | – | ﹤0.01% | 784 |
|
|
2021
Q1 | $0 | Hold |
86
| – | – | ﹤0.01% | 788 |
|
|
2020
Q4 | $0 | Hold |
86
| – | – | ﹤0.01% | 751 |
|
|
2020
Q3 | $0 | Buy |
+86
| New | – | ﹤0.01% | 721 |
|